Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response.
Xiaoqiang QiMing YangLixin MaMadeline SauerDiego AvellaJussuf T KaifiJeffrey BryanKun ChengKevin F Staveley-O'CarrollEric T KimchiGuangfu LiPublished in: Journal for immunotherapy of cancer (2021)
Sunitinib enables RFA-released in situ TSA to ignite an effective anti-tumor immune response by suppressing HGF and VEGF signaling pathways. Sunitinib-RFA as a synergistic therapeutic approach significantly suppresses HCC growth.
Keyphrases
- radiofrequency ablation
- immune response
- metastatic renal cell carcinoma
- renal cell carcinoma
- signaling pathway
- papillary thyroid
- dendritic cells
- toll like receptor
- endothelial cells
- squamous cell
- vascular endothelial growth factor
- cancer therapy
- inflammatory response
- oxidative stress
- drug delivery
- childhood cancer